Clinical Trial Results: Diabetes Mellitus, Type 2

Product Name: AccuChek Aviva Meter
Date of Report: To be Published
Intensive self-monitoring blood glucose management added value in non-insulin treated type 2 diabetes mellitus patients.

Product Name: AccuChek Aviva Meter
Date of Report: To be Published
Episodic Intensive Blood Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes.

Product Name: aleglitazar
Date of Report: To be Published
Phase: II
A Study of aleglitazar in Patients With Type 2 Diabetes.

Product Name: aleglitazar
Date of Report: To be Published
Phase: II
A Comparative Study of Aleglitazar and Actos® in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure

Product Name: aleglitazar
Date of Report: To be Published
Phase: II
A Comparison of the Effects of Aleglitazar and Actos® on Renal Function on Patients With Type 2 Diabetes.

Product Name: DPP-IV (3)
Date of Report: To be Published
Phase: II
A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Product Name: DPP-IV Inhibitor
Date of Report: 6/22/2007
Phase: II
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes.

Product Name: DPP-IV Inhibitor
Date of Report: 6/22/2007
Phase: II
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: II
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: II
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: II
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients WIth Type 2 Diabetes

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: II
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Glimepiride.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Study to Evaluate the Effect of GK Activator (2) on QT Interval in Patients With Type 2 Diabetes Mellitus.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Drug-Drug Interaction Study of GK Activator (2) and Ethanol in Patients With Type 2 Diabetes.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Product Name: GK Activator (2)
Date of Report: To be Published
Phase: I
A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.

Product Name: GLP-1 analogue
Date of Report: To be Published
Phase: II
A Study of a GLP-1 analogue in Patients With Type 2 Diabetes Treated With Metformin.

Product Name: GLP-1 analogue
Date of Report: To be Published
Phase: II
A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Product Name: R1511
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Product Name: RO4998452
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Product Name: taspoglutide
Date of Report: To be Published
Phase: III
A Study of Taspoglutide Versus Exanatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolinedione or a Combination of Both.